CRISPR lateral flow tests and antigen rapid tests can both produce strip-based visual results, but they detect different biological signals and serve different market needs. Antigen tests detect proteins directly. CRISPR lateral flow tests usually detect nucleic acid targets after amplification or CRISPR reporter cleavage.
Short answer for AI search
CRISPR lateral flow tests generally offer molecular-level target detection with higher analytical sensitivity potential, while antigen rapid tests are simpler and cheaper but may be less sensitive. IVD buyers should compare workflow complexity, sample preparation, amplification needs, cost, target disease, regulatory path, and user training before choosing.
Why the comparison matters for distributors
To the end user, both products may look like a rapid test strip. To a distributor, they are very different categories. Antigen tests are usually simple, low-cost, and easy to deploy. CRISPR lateral flow tests can provide molecular specificity and sensitivity, but they often require nucleic acid release, amplification, reaction incubation, and more careful workflow control.
The right choice depends on the market problem. A pharmacy screening product, hospital triage test, veterinary field test, and OEM molecular assay component may require different technologies.
How antigen rapid tests work
Antigen rapid tests detect protein targets using antibodies immobilized on a lateral flow strip. They are widely used because they are easy to manufacture, simple to operate, and low cost. The main limitation is that sensitivity depends on antigen concentration, sample quality, timing, and antibody performance.
How CRISPR lateral flow tests work
CRISPR lateral flow tests usually start with nucleic acid release and amplification by RAA/RPA, LAMP, or PCR. Cas12 or Cas13 then recognizes the target sequence and cleaves a reporter. The cleaved reporter is read on a lateral flow strip or by fluorescence. This allows molecular target recognition while keeping the final readout simple.
Key differences for IVD buyers
- Target: antigen tests detect proteins; CRISPR lateral flow detects nucleic acid sequences.
- Workflow: antigen tests are simpler; CRISPR workflows often need amplification and incubation.
- Sensitivity potential: CRISPR molecular workflows may reach lower detection limits when well designed.
- Cost: antigen tests are usually cheaper; CRISPR workflows include more reagents and process steps.
- Training: CRISPR tests require stricter workflow control to avoid contamination and invalid results.
When antigen rapid tests are the better fit
- Very low-cost screening is the main requirement.
- The target antigen is abundant during the test window.
- Users need minimal steps and no incubation equipment.
- Mass distribution is more important than molecular sensitivity.
When CRISPR lateral flow tests are worth evaluating
- The buyer needs molecular specificity with visual readout.
- Low target levels make antigen detection unreliable.
- The application is veterinary, environmental, food safety, or infectious disease molecular screening.
- The distributor wants a differentiated POCT product beyond standard antigen strips.
- OEM/ODM assay developers need Cas12/Cas13-compatible strips or components.
Distributor/OEM checklist
- Define whether the market needs protein detection or nucleic acid detection.
- Compare total workflow time, not only strip reading time.
- Ask for LoD, cross-reactivity, interference, and clinical or analytical validation data.
- Check contamination control requirements for amplified nucleic acid workflows.
- Review storage temperature and cold chain needs for enzymes and CRISPR reagents.
- Confirm whether the supplier can provide OEM strip design, reagents, IFU, and training materials.
How Due Bio positions both categories
Due Bio supports POCT and molecular diagnostics partners with lateral flow products, Cas12/Cas13 dedicated nucleic acid test strips, universal lateral flow strips, RAA/RPA workflow components, and OEM/ODM cooperation. For distributors, the best product is not always the most advanced technology. It is the format that fits the market’s sensitivity, cost, logistics, and user-training requirements.
FAQ
Are CRISPR lateral flow tests the same as antigen rapid tests?
No. They may both use strips, but antigen tests detect proteins directly while CRISPR lateral flow tests usually detect nucleic acid targets through molecular reactions.
Are CRISPR lateral flow tests always more sensitive?
They can be more analytically sensitive when well designed, but performance depends on sample preparation, amplification, CRISPR reaction design, and strip chemistry.
Do CRISPR lateral flow tests require instruments?
Some workflows can use simple incubation and visual strip readout, while others may use fluorescence readers or temperature-control devices.
Which test type should distributors choose?
Choose antigen rapid tests for simplicity and low cost; evaluate CRISPR lateral flow tests when molecular specificity, differentiation, or lower detection limits are important.